On the filings, Bristol Myers Squibb (BMY) is the stronger stock right now — higher on our blended fundamentals-plus-verdict read, and we currently rate it HOLD.
Cheap, ~4.6%-yielding pharma cash machine — but a guided 2026 generic cliff and IRA pricing on Eliquis cap upside; own for income, don't chase.
Humira cliff cleared — revenue reaccelerating to +9% and $19B cash flow fund a rich dividend, but the price is full.
| Metric | BMY | ABBV |
|---|---|---|
| Fundamentals score | 74 | 58 |
| Revenue growth (YoY) | -0.2% | +8.6% |
| Net income growth (YoY) | +178.8% | -1.2% |
| Net margin | 14.6% | 6.9% |
| Return on equity | 38.2% | — |
| ROIC (est.) | — | — |
| Liabilities / Equity | 3.87 | — |
| Piotroski F-score | 8 / 9 | 6 / 9 |
Bold green = the stronger figure. All rows derive from SEC XBRL filings — no market-price data on this page.
AI-generated analysis, produced by our proprietary engine from SEC filing data.
Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jun 19, 2026, 2:27 PM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.
AI-generated analysis, produced by our proprietary engine from SEC filing data.
Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jul 6, 2026, 9:31 PM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.